{"id":"NCT02451150","sponsor":"Takeda","briefTitle":"A Phase 3 Pharmacokinetic Study of TAK-536 (Azilsartan) in Pediatric Patients 6 to Less Than 16 Years With Hypertension","officialTitle":"An Open-label, Phase 3, Multicenter Study to Evaluate the Pharmacokinetics Following a Single Oral Dose of TAK-536 in Pediatric Patients 6 to Less Than 16 Years of Age With Hypertension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-08","primaryCompletion":"2015-09","completion":"2015-09","firstPosted":"2015-05-21","resultsPosted":"2016-04-07","lastUpdate":"2016-04-07"},"enrollment":6,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Pediatric Hypertension"],"interventions":[{"type":"DRUG","name":"Azilsartan","otherNames":["TAK-536"]}],"arms":[{"label":"Azilsartan 5 mg","type":"EXPERIMENTAL"},{"label":"Azilsartan 10 mg","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the pharmacokinetics and safety of a single dose of TAK-536 (azilsartan) in pediatric patients aged 6 to less than 16 years with hypertension.","primaryOutcome":{"measure":"AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to Time 24 Hours of TAK-536 (Azilsartan)","timeFrame":"Pre-dose and at multiple time points (up to 24 hours) post-dose","effectByArm":[{"arm":"Azilsartan 5 mg","deltaMin":6350.3,"sd":2963.53},{"arm":"Azilsartan 10 mg","deltaMin":6871.7,"sd":893.93}],"pValues":[]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":3,"countries":["Japan"]},"refs":{"pmids":["30027478"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":3},"commonTop":["Gastroenteritis"]}}